As of 2024-12-13, the Relative Valuation of Innate Pharma SA (IPH.PA) is (3.89) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 1.55 EUR, the upside of Innate Pharma SA based on Relative Valuation is -351.0%.
The range of the Relative Valuation is (3.37) - (3.37) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.0x - 15.9x | 12.0x |
| Forward P/E multiples | 5.1x - 8.0x | 6.6x |
| Fair Price | (3.37) - (3.37) | (3.89) |
| Upside | -317.1% - -317.1% | -351.0% |
| Date | P/E |
| 2024-12-11 | -3.80 |
| 2024-12-10 | -4.03 |
| 2024-12-09 | -3.95 |
| 2024-12-06 | -3.52 |
| 2024-12-05 | -3.24 |
| 2024-12-04 | -3.39 |
| 2024-12-03 | -3.27 |
| 2024-12-02 | -3.25 |
| 2024-11-29 | -3.39 |
| 2024-11-28 | -3.42 |
| 2024-11-27 | -3.37 |
| 2024-11-26 | -3.40 |
| 2024-11-25 | -3.39 |
| 2024-11-22 | -3.64 |
| 2024-11-21 | -3.63 |
| 2024-11-20 | -3.77 |
| 2024-11-19 | -3.49 |
| 2024-11-18 | -3.57 |
| 2024-11-15 | -3.42 |
| 2024-11-14 | -3.62 |
| 2024-11-13 | -3.84 |
| 2024-11-12 | -4.00 |
| 2024-11-11 | -3.94 |
| 2024-11-08 | -3.83 |
| 2024-11-07 | -3.86 |
| 2024-11-06 | -3.87 |
| 2024-11-05 | -3.88 |
| 2024-11-04 | -3.97 |
| 2024-11-01 | -4.05 |
| 2024-10-31 | -4.11 |
| 2024-10-30 | -4.10 |
| 2024-10-29 | -4.02 |
| 2024-10-28 | -3.98 |
| 2024-10-25 | -4.04 |
| 2024-10-24 | -3.87 |
| 2024-10-23 | -4.05 |
| 2024-10-22 | -4.14 |
| 2024-10-21 | -4.28 |
| 2024-10-18 | -4.45 |
| 2024-10-17 | -4.50 |
| 2024-10-16 | -4.56 |
| 2024-10-15 | -4.52 |
| 2024-10-14 | -4.54 |
| 2024-10-11 | -4.56 |
| 2024-10-10 | -4.57 |
| 2024-10-09 | -4.59 |
| 2024-10-08 | -4.64 |
| 2024-10-07 | -4.65 |
| 2024-10-04 | -4.65 |
| 2024-10-03 | -4.68 |